Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Sep 07, 2014 12:15pm
217 Views
Post# 22913684

RE:RE:RE:Small Sign: Clinical Trial For RVX-208 Soon To Commence

RE:RE:RE:Small Sign: Clinical Trial For RVX-208 Soon To CommenceHi SanFran. Well put. I couldn't agree more. 

It would not cost them any significant amount of money to communicate.

In terms of content it does not just have to be directly related to RVX or Zenith related activities. Themes could be about the larger context of BET inhibition and scientific papers related to this and the new theories related to inflammation and it's damaging effects across many diseases. All of this communication could be juxtaposed with and put in the context of the RVX and Zenith brands (e.g.information brought to you by...).

The available stories are almost unlimited and positive. All it requies is a creative mind. The blogs could be continuous.

Sources of information could come from proprietary research, published reasearch, books such as Grain Brain, etc all promoting the concept of BET inhibition and it's impact on diabetes mialitis, heart disease, various cancers, Alzheimers, etc.

Anyway, they should be smart enough to be dealing with this but obviously it is not on their agenda.

We really shouldn't be spending our time telling them what they need to do but I guess it's a matter of self preservation of assets.

It's a simple problem to solve - "RVX, please tell us your plan".

On another point one of the posters indicated, if I understood it correctly, that it would be very difficult to recruit for RE-MACE. Does this mean that very few of these types of patients exists? If so it implies that the market for rvx-208 may be extremely limited and this contradicts all of the evidence I've seen.

GLTA
toinv




Bullboard Posts